ALTITUDE‐AD: Cost Savings Using a pTau217 Screening Assay in an Ongoing Phase 2 Study of Sabirnetug in Early Alzheimer's Disease
Participants tested by amyloid PET or CSF Aβ42/40 were enriched for meeting amyloid-based inclusion criteria and the screening cost was reduced by approximately US $10 million (∼40%). Additionally, the pTau217 screening strategy helped reduce the unnecessary burden of PET scans and LP procedures for potential participants.
Authors
- Vladimir Skljarevski
- Maddelyn A. Hyland
- Eric Siemers
- June Kaplow
- Robert A. Dean
- Gopalan Sethuraman
- Siew Tin Gan
- Jasna Jerecic
- Karen Sundell
- Drew Haigh
- Todd Feaster
- Prajakta Dinesh Mangeshkar
Institutions
- Acumen Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_100249
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00